US Food and Drug Administration approves Teva leukemia drug

October 26, 2012 17:20

The US Food and Drug Administration on Friday said it has approved a new leukemia treatment from Israel-headquartered Teva Pharmaceutical Industries Ltd to be sold under the brand name Synribo.

The drug, also known as omacetaxine mepesuccinate, is approved to treat a type of the blood and bone marrow cancer called chronic myelogenous leukemia, or CML, in patients whose cancer has progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors.

"Today's approval provides a new treatment option for patients who are resistant to or cannot tolerate other FDA-approved drugs for chronic or accelerated phases of CML," Richard Pazdur, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and Research, said in a statement.

Related Content

Breaking news
March 18, 2018
Report: Syrian army gives Harasta rebels until 3 p.m. to withdraw


Israel Weather
  • 15 - 31
    Beer Sheva
    17 - 28
    Tel Aviv - Yafo
  • 16 - 25
    16 - 26
  • 23 - 31
    16 - 31